CLGN's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.45 * Ranked among companies with meaningful Forward Dividend Yield % only.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
CollPlant Biotechnologies Forward Dividend Yield % Related Terms
CLGN vs CPMV, TCRT, DRMA: Forward Dividend Yield % Comparison
For the Biotechnology subindustry, CollPlant Biotechnologies's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CollPlant Biotechnologies Forward Dividend Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CollPlant Biotechnologies's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where CollPlant Biotechnologies's Forward Dividend Yield % falls into.
What does a Forward Dividend Yield % of 0.00% mean?
CollPlant Biotechnologies (CLGN) has a Forward Dividend Yield % of 0.00% as of Jul. 01, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on CollPlant Biotechnologies and its competitors. According to the industry distribution chart, CollPlant Biotechnologies ranks #999999 out of 147 companies in the Biotechnology industry.
Is CollPlant Biotechnologies' Forward Dividend Yield % too high?
CollPlant Biotechnologies' current Forward Dividend Yield % is 0.00%. Based on the distribution chart, CollPlant Biotechnologies ranks #999999 out of 147 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, CollPlant Biotechnologies has a GF Score™ of 35/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CollPlant Biotechnologies' Forward Dividend Yield % compare to CPMV and TCRT?
According to the Biotechnology industry distribution chart, CollPlant Biotechnologies ranks #999999 out of 147 companies for Forward Dividend Yield %. This places CollPlant Biotechnologies in the lower half of its industry. The industry median Forward Dividend Yield % is 1.45. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Biotechnology company?
The median Forward Dividend Yield % among Biotechnology companies is 1.45, based on 147 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on CollPlant Biotechnologies and its competitors. For the Biotechnology industry, the median Forward Dividend Yield % is 1.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CollPlant Biotechnologies's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CollPlant Biotechnologies stock overvalued right now?
Based on GuruFocus' analysis, CollPlant Biotechnologies (CLGN) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.29, compared to a current price of $0.34 — trading 17.3% above its estimated fair value. The current Forward Dividend Yield % is 0.00%. CollPlant Biotechnologies' overall GF Score™ is 35/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For CollPlant Biotechnologies (CLGN), the current Forward Dividend Yield % is 0.00% as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CollPlant Biotechnologies (CLGN) Overvalued in 2026?
Based on GuruFocus' analysis, CollPlant Biotechnologies stock appears to be overvalued.
The current stock price of $0.34 is trading 17.3% above its estimated GF Value™ of $0.29.
GuruFocus considers CollPlant Biotechnologies to be Modestly Overvalued.
Key valuation signals for CLGN:
Forward Dividend Yield %: 0.00%
GF Value™: $0.29 vs. price of $0.34 (17.3% above fair value)
No single metric tells the full story. See the CLGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives majority revenue, Canada, Europe and Other, and Israel.
35GF Score
Get the complete analysis for CLGN
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLGN has been successfully added to your 